

19 August 2025

BlinkLab Presenting This Week at the TechKnow Invest Roadshow Conference

BlinkLab Limited (ASX:BB1) (“BlinkLab”, or the “Company”), a leading digital healthcare innovator, is pleased to announce that it will be presenting at the TechKnow Invest Roadshow conference this week in both Melbourne and Sydney, Australia.

Mr Brian Leedman, BlinkLab’s Chairman, will be presenting at:

TechKnow Invest Roadshow – Melbourne

Time: 12:45pm, Tuesday 19 August 2025

Location: Rydges Melbourne, VIC

Registration: <https://www.techknowinvestroadshow.com.au/>

TechKnow Invest Roadshow – Sydney

Time: 12:45pm, Thursday 21 August 2025

Location: Swissôtel Sydney, NSW

Registration: <https://www.techknowinvestroadshow.com.au/>

Recordings of the presentations at the conference can be viewed at the link below:

<https://www.youtube.com/channel/UChiCDdyxidvyEP9Rkks-DRA>

The Company’s most recent investor presentation is below this ASX Announcement.

This announcement has been approved by the Board of Directors

For further information please contact:

Dr. Henk-Jan Boele

Chief Executive Officer

henkjan@blinklab.org

M: +31 (0) 611 132 247

Brian Leedman

Non-Executive Chairman

brian@blinklab.org

M: +61 (0) 412 281 780



About BlinkLab Limited

BlinkLab, a company founded by neuroscientists at Princeton University, over the past several years has fully developed a smartphone based diagnostic platform for autism, ADHD, schizophrenia, and other neurodevelopmental conditions. Our most advanced product is an autism diagnostic test that leverages the power of smartphones, AI and machine learning to deliver screening tests specifically designed for children as young as 18 months old. This marks a significant advancement, considering traditional diagnoses typically occur around five years of age, often missing the crucial early window for effective intervention. BlinkLab is led by an experienced management team and directors with a proven track record in building companies and vast knowledge in digital healthcare, computer vision, AI and machine learning. Our Scientific Advisory Board consists of leading experts in the field of autism and brain development allowing us to bridge most advanced technological innovations with groundbreaking scientific research.

blinklab *(ASX:BB1)*

Early and Accurate Diagnosis of Autism and ADHD

Introducing an AI-powered smartphone
platform for neurological testing

August 2025
Brian Leedman, Chairman



Disclaimer

This presentation has been prepared by BlinkLab Limited (ACN 652 901 703) (**BlinkLab** or **Company**) and contains background information about BlinkLab's current operations at the date of this presentation. The presentation is in summary form and does not purport to be all inclusive or complete.

Recipients should conduct their own investigations and perform their own analysis in order to satisfy themselves as to the accuracy and completeness of the information, statements and opinions contained in this presentation. This presentation is for information purposes only. Neither this presentation nor the information contained in it constitutes an offer, invitation, solicitation or recommendation in relation to the purchase or sales of shares or other securities in any jurisdiction. This presentation is not a prospectus, product disclosure statement or other offering document under Australian law (and will not be lodged with the Australian Securities and Investments Commission) or any other law.

This presentation does not constitute investment or financial product advice (nor tax, accounting or legal advice) and has been prepared without taking into account the recipient's investment objectives, financial circumstances or particular needs and the opinions and recommendations in this presentation are not intended to represent recommendations of particular investments to particular persons. Recipients should seek professional advice when deciding if an investment is appropriate. All securities involve risks which include (among others) the risk of adverse or unanticipated market, financial or political developments.

This presentation may include forward-looking statements. Forward-looking statements are only predictions and are subject to risks, uncertainties and assumptions which are outside the control of BlinkLab. Actual results or events may be materially different to those expressed or implied in this presentation. Given these uncertainties, recipients are cautioned not to place reliance on forward looking statements.

Corporate Snapshot

Next-Generation Digital Solutions for Neurodevelopmental Health



CAPITAL STRUCTURE	
ASX Code	BB1
Shares on Issue	125M
Options on Issue	44M
Founders’/ Directors’ percentage	24%
Market Cap (30 July 2025)	\$55.7M
Cash (30 June 2025)	\$8.7M



Henk-Jan Boele,
Cofounder & CEO

MD, PhD, Entrepreneur
and Neuroscientist at
Erasmus MC and
Princeton University



Anton Uvarov, Co-founder,
COO & Executive Director

MBA, PhD, Biotech
Analyst with Citibank



Bas Koekkoek
Cofounder & CSO

PhD, Assistant Prof. of
Neuroscience, Erasmus MC



Peter Boele
Cofounder & CTO

MA, Startup Entrepreneur,
PhD Candidate at
Erasmus MC



Brian Leedman
Non-Executive Chairman

Experienced Chairman and
Co-Founder of six ASX-listed
Healthcare Companies



Jane Morgan
Director

18+ Years Experience in
Strategic Investor &
Media Relations



Richard Hopkins
Director

20+ Years in Corporate
Leadership Roles with Public
Biotechnology Companies

What is Autism?

Neurodevelopmental condition that affects how the brain processes sensory information.

Autism can impact:

- Social development
- Language development
- Sensory processing
- Behavior and interests



Economic Burden of Autism in USA: \$700B in 2024


"The economic burden is significant and alarming" ¹

Prevalence has grown up to 2-4% among children²

Autism healthcare expenses are soaring³

- *Costs for an autism diagnostic evaluation: \$1,000 to \$7,000*
- *Lifetime cost for individual with ASD: \$3.6M³*

Autism prevalence studies of children, per 10,000



SOURCE: MAATHU RANJAN

¹ Leigh and Du (2015), Forecasting the economic burden of autism in 2015 and 2025 in the US, Journal of Autism and Developmental Disorder


² Center for Disease and Control, World Health Organization

³ Cakir et al. (2020) The lifetime social cost of autism: 1990-2029, Research in Autism Spectrum Disorder

⁴ National Disability Insurance Scheme (NDIS)

NDIS Payments for Autism in Australia: A\$8.4B in 2024

NDIS payments for autism rise by more than 20% annually, with the largest share allocated to Supervised Independent Living (SIL).



Data extracted and visualized by BlinkLab. Extracted from National Disability Insurance Scheme (NDIS).

Consensus: Early diagnosis and intervention enhance independent living skills in people with autism.

Recommendation by the American Academy of Pediatrics:



“All children must be screened for autism at ages 18 and 24 months”

Market size = Total number of children born each year:

- US 3.6M
- EU 3.8M
- AU 287K

More reading:

1. National Research Council, Committee on Educational Interventions for Children with Autism. *Educating Children With Autism*. Lord, C., McGee, J. P., eds. Washington, DC: National Academies Press; 2001.
2. Olley, J. G. (2005). Curriculum and classroom structure. In: Volkmar, F. R., Paul, R., Klin, A., Cohen, D. (Eds.), *Handbook of Autism and Pervasive Developmental Disorders*. 3rd ed. Vol II (863–881). Hoboken, NJ: John Wiley & Sons.
3. Helt, M., Kelley, E., Kinsbourne, M., Pandey, J., Boorstein, H., Herbert, M., et al. (2008). Can children with autism recover? If so, how? *Neuropsychology Review*, 18(4), 339–366.
4. Rogers, S. J., & Lewis, H. (1989). An effective day treatment model for young children with pervasive developmental disorders. *Journal of the American Academy of Child and Adolescent Psychiatry*, 28(2), 207–214.
5. Reichow, B., & Wolery, M. (2009). Comprehensive synthesis of early intensive behavioral interventions for young children with autism based on the UCLA young autism project model. *Journal of Autism and Developmental Disorders*, 39(1), 23–41.

THE AUSTRALIAN

YOUNG CHILDREN JOINING SCHEME 400 PER CENT HIGHER THAN EXPECTED

NDIS misses autism checks

EXCLUSIVE

STEPHEN LUNN
SARAH ISON

Thousands of children with autism or developmental delay who should not be on the \$42bn National Disability Insurance Scheme are still getting taxpayer support because public servants are failing to reassess their cases.

The NDIS caseload surged last year, as the number of children up to six years old who joined the scheme skyrocketed 400 per cent more than expected.

In the latest NDIS annual financial sustainability report, scheme actuary David Gifford notes greater numbers of children

with developmental delay joining the scheme in 2022-23 pushed numbers significantly higher than anticipated.

More than 16,500 0 to 6-year-olds joined the NDIS last financial year, 415 per cent greater than the 3,211 expected. An additional 23,766 people across all age groups joined the scheme in 2022-23 with developmental delay as their primary disability, when just 5,440 were anticipated.

Despite the National Disability Insurance Agency's inability to predict the recent massive increases, the scheme actuary still projects between five and six per cent of the 300,000 children aged 0-14 on the NDIS are likely to be removed each year for the next three years as staffing resources

Freed non-citizen detainees accused of 27 crimes

DAVID MURRAY
JESS MALCOLM

Non-citizens released into the community after the High Court's "NZYQ" ruling in November have since been accused of committing 27 crimes, with more than 100 of

them receiving welfare benefits.

The Australian Federal Police's Grant Nicholls told a Senate estimates committee on Tuesday night that as of last Friday, the AFP had received 27 reports of crimes involving former detainees. Seven were commonwealth prosecutions, 18 were state and territory prosecutions and one matter was under consideration.

FULL REPORT P5
COMMENT P5

ramp up. The revelations came as NDIS executives fronted parliament on Wednesday and conceded \$60bn in projected savings would likely disappear altogether

if Labor's efficiency measures fail. Former NDIS minister Linda Reynolds led a united front of Coalition and Greens senators attacking the Albanese Govern-

ment's secrecy over its plans to contain the scheme's growth over the next decade.

Senator Reynolds grilled officials on whether the scheme was still running "above expectations", to which she was told the cost of the NDIS was 0.9 per cent above expectations as of last September.

The WA senator also asked the NDIS executives what would happen if Labor's \$720m in budgeted "efficiency measures" – which the government says will get the scheme's growth down

to 8 per cent successful.

"It will result in not being \$60bn ... in Reynolds said. Mr Gifford

quick calculations, yes, it would be something like that".

Despite admitting that the NDIS's third quarter report was available and in the hands of commonwealth and state governments, the officials refused to table the documents or provide budget data over the past four months.

Greens senator Jordan Steele-John criticised the agency for setting a "dangerous precedent" while Senator Reynolds blasted what she called an "unprecedented" lack of transparency.

Recent cases saw an overall increase in NDIS participant numbers in 2022-23 of 25,847, 32 per cent more than the 57,639 the actuary had expected.

"New entrants with developmental delay and autism accounted for 30 per cent of total new entrants in 2022-23," the actuary's paper says.

About 12 per cent of all boys aged 5-7 are on the NDIS.

Total scheme numbers sat at 610,500 at the end of 2022-23 and are projected to increase to over a

Average wait time for autism assessments in children is over 3 years



6 February 2023

New research has revealed that children wait 3.5 years on average for neurodevelopment assessments.

Sources:


Left up - The Australian 15 February 2014;

Right down - Sydney University 6 February 2023, www.sydney.edu.au/brain-mind;

Autism diagnosis is expensive, inefficient, and often late

The costly labor and time-intensive diagnostic evaluations are unnecessary for many children

3-5 years of uncertainty for family and child




Currently, a clinical autism diagnosis requires input from multiple disciplines.

Long waitlists because of extreme shortage of specialists that can diagnose autism. Total time for evaluation is between 3-8 hours.

BlinkLab's digital solution accelerates path to diagnosis

The costly labor and time-intensive diagnostic evaluations are unnecessary for many children.


Diagnosis in weeks to months



BlinkLab diagnosis is instantaneous after completing the two 15-minute video session. Only necessary specialists will need to be consulted. BlinkLab is currently conducting their FDA 510(k) regulatory study.

Our patented solution: Neuroscience on a smartphone

Minuscule facial reflexes, evoked by our app, generate a digital biomarker for autism.



Evokes Facial Reflexes

By presenting visual and auditory stimuli during smartphone use.

Computer Vision

Facial features are tracked on the smartphone and transferred to the **BlinkLab platform**.


Biomarker Detection

Biomarkers are detected in **real-time** and made available to the clinician.

Evaluates brain function


State-of-the art analysis methods and AI modelling to **map the functioning of brain regions involved in autism**.

Beyond blinks: Tracking of vocal responses and hand/head movements as objective markers for autism



Large Study Validates and Enhances BlinkLab's Accuracy in Detecting Autism in Children¹

Released on 19 November 2024



In a sample of 441 children, BlinkLab achieved a **sensitivity of 91%** and **specificity of 85%**

1) ASX Announcement (19 November 2024) - Large-Scale Study Validates and Enhances BlinkLab's Accuracy in Detecting Autism in Children

BlinkLab Outperforms FDA-approved Digital Peers

We are leaders in the digital diagnostics and therapeutics space

blinklab

cognoa

ETD
EarliTec Diagnostics Inc.



Sensitivity

91%

52%*

71%



Specificity

85%

19%*

81%



Smartphone-based

Ye

Ye

No



FDA approval


No - 510(k)

Yes - *De Novo*

Yes - 510(k)


* Calculated over all study completers (Cognoa's device yielded indeterminate results in 68% of cases)

Our AI technology detects autism and ADHD



BlinkLab precisely measures **sensory sensitivity** in people with autism and ADHD.

First product to monitor the effect of therapy in real-time



Real-time drug monitoring offers a path to even larger recurring revenues via subscription-based models.

We are experts in science, tech and commercialization



Henk-Jan Boele, CEO

MD, PhD, Entrepreneur and neuroscientist at Erasmus MC and Princeton University

Fifteen years of experience in neurobehavioral testing with over 35 publications. Recipient of many prestigious awards. Team leader and inventor of BlinkLab.



**Anton Uvarov, COO
Executive director**

MBA, PhD, Biotechnology Analyst with Citibank

Cofounder of two biotechnology companies, developed therapeutics for neurodegenerative disorders. Both successfully IPO and publicly traded.



Bas Koekkoek, CSO

PhD, Assistant Professor of Neuroscience. Erasmus MC

Twenty-six years of experience in neurobehavioral testing with over 55 publications in IEEE and the field of neuroscience. An innovator in heart and soul. Cofounder of Neurasmus BV.



Peter Boele, CTO

MA, PhD candidate, Erasmus MC

Born to code, with over 20 years of experience in software development, both as developer as well as executive.



Our mission is to use neuroscience to improve the daily life of families with autism.

We are backed up by an expert advisory board

Company Chairman



Brian Leedman

Experienced Chairman and co-founder of six ASX listed healthcare companies including digital healthcare company ResApp Health, acquired by Pfizer for \$180M in 2022.



Company Director



Jane Morgan

Providing strategic investor and media relations services for over 16 years. Founder of JMM.



Company Director



Richard Hopkins

Experienced bio-pharmaceutical executive with over 20 years in corporate leadership roles with public biotechnology companies.



Scientific advisor



Prof. Samuel Wang

Professor of Neuroscience at Princeton University and author of 2 bestselling books.



Scientific advisor



Prof. Chris De Zeeuw

Professor of Neuroscience at Erasmus MC and vice-director of the NIN (Netherlands Institute of Neuroscience).



Scientific advisor



Prof. Javier Medina

Professor in neuroscience at Baylor College of Medicine in Houston.



World leading scientists, strategic and commercial advisors.

Intellectual property

Our patents prohibit other parties to conduct neurometric testing using mobile devices.



BlinkLab has consistently prioritized the development and protection of its intellectual property since its seed funding round in August 2021. Our capital investments sourced from seed investors, government funding, and industry sponsorships - have been primarily utilized for IP and software development.



We are represented by the US-based law firm, Meagher Emanuel Laks Goldberg & Liao, LLP, which ensures our IP protection. We have filed National Stage Applications for 2020-2021 patents across various jurisdictions including the United States, Japan, Canada, Australia, Korea, and the European Patent Office (EPO) in March 2023.



Our portfolio comprises patents filed both by Princeton University, under an exclusive license agreement, and BlinkLab itself. These patents range from systems for neurobehavioral testing to methods for measuring emotional engagement, all of which firmly establish our innovation and leadership in the field.



Patents filed by Princeton University, with an exclusive license agreement in place between Princeton University and BlinkLab:

- PCT application number PCT/US2021/058698 Filed November 10, 2021, entitled “System and Method for Remote Neurobehavioral Testing”
- US patent application number 18/036,009 Filed May 9, 2023, entitled “System and Method for Remote Neurobehavioral Testing”
- European patent application number 21892692.1 Filed March 31, 2023, entitled “System and Method for Remote Neurobehavioral Testing”
- Japanese patent application number 2023-528017 Filed May 10, 2023, entitled “System and Method for Remote Neurobehavioral Testing”
- Canadian patent application number 3,195,596 Filed April 13, 2023, entitled “System and Method for Remote Neurobehavioral Testing”
- Korean patent application number 10-2023-7018839 Filed June 2, 2023, entitled “System and Method for Remote Neurobehavioral Testing”
- Australian patent application number 2021378273 Filed May 23, 2023, entitled “System and Method for Remote Neurobehavioral Testing”




Patents filed by BlinkLab:

- US Provisional patent application number 63/218,607 Filed on November 30, 2022, entitled “Psychopharmacological System and Method Using Eyelid Tracking”
- US Provisional patent application number 63/460,451 Filed on April 19, 2023, entitled “Method And System For Measuring Emotional Engagement”
- US Provisional patent application number 63/548,542 Filed on February 1, 2024, entitled “System And method For Detecting Neurological Condition”

Discuss the progress and the structure of the US FDA study. What is the timing of the US FDA study?

510(k) Trial: Prospective, multicenter, double-blinded, within-subject comparison study



*Main Study: N = 260 children with autism,
and N = 260 children without autism.*

- 
- Q4 2024** - CRO assigned*
 - IRB approval for initial 100-patient study*
 - Pre-submission meeting with FDA*¹
 - Q1 2025** - Onboarded two US clinical sites for initial study: PriMED and NorthShore Pediatrics*^{2,3}
 - Compliant with HIPAA and 21 CFR parts 11, 820*
 - Started data collection for initial study*⁴
 - Q2 2025** - IRB approval for main 520-patient study⁵
 - Onboarding clinical and research sites for main study^{6,7}
 - Q3 2025** - Results from initial study
 - Start main study
 - Q2 2026** - Results from main study
 - Submission to FDA
 - Q3 2026** - Outcome from FDA 510(k) submission
- * completed

1) ASX Announcement (19 December 2024) - Positive Outcome from FDA Pre-Submission Meeting

2) ASX Announcement (5 February 2025) - BlinkLab Initiates its First US-based Clinical Site for Autism Diagnostic Registrational Trial

3) ASX Announcement (10 February 2025) - North Shore Pediatric Therapy in Chicago Joins BlinkLab's US Registrational Study

4) ASX Announcement (12 March 2025) - BlinkLab Commences U.S. Autism Diagnostic Study with First Child Tested

5) ASX Announcement (30 June 2025) - BlinkLab Receives US Ethics Approval for the Main Phase of FDA 510(k) Diagnostic Trial

6) ASX Announcement (22 May 2025) - BlinkLab Engages First Clinical Site for Main Study Phase of FDA 510(k) Diagnostic Trial

7) ASX Announcement (8 July 2025) - BlinkLab Expands U.S. Clinical Trial Network: University of Nebraska Medical Center Engaged as Second Site in Main Phase of FDA 510(k) Study

What learnings are expected from the FDA Pilot Study?

- Final validation of BlinkLab Dx 1 in a 'real-FDA-study-situation' (*proposed announcement in Q3 2025*)
- Optimize SOPs for clinicians and families - protocols
- Optimize recruitment strategies
- Evaluate and optimize usability of the BlinkLab platform



North Shore Pediatric Therapy
(Chicago, Illinois).



PriMED Clinical Research LLC
(Dayton, Ohio)

PriMED Clinical Research Autism Device Study


Study Name: The Evaluation of the Diagnostic Accuracy of BlinkLab's Digital Assessments for Autism

Purpose:

PriMED is hosting a research study that is to validate whether BlinkLab's (Name of Sponsor) neurobehavioral assessments, using a computer program to measure how a child responds to different sights, sounds, and touches, as well as their repetitive behaviors. By analyzing these responses with smart computer programs (machine learning), they can reliably tell apart children with autism from those without it.

What is the minimum level of accuracy - sensitivity & specificity? Which is more important? What has been achieved to date?

- For FDA approval, minimum requirement for both is 65%
- From clinical perspective, specificity is more important. Current questionnaire screeners aim for high sensitivity at the expense of specificity.
- **To date: BlinkLab Dx 1 Sensitivity 91% and Specificity 85% based on 441 patients**



Why is there a difference between diagnosing autism in adults and in children?

	Children	Adults
Observation Source	Parents, teachers, clinicians	Self-report, limited external observation
Tools Used	ADOS, M-CHAT, Vineland	Limited, AQ, RAADS-R, interviews
Symptom Presentation	More visible behaviors	Masked, internalized symptoms
Developmental History	Actively observed	Retrospective or missing
Diagnostic Challenge	Early recognition	Masking, co-morbidity, late awareness

BlinkLab is running study with University of Amsterdam and Netherlands Autism Register on adult diagnosis, with focus on women¹. There is **no masking possible in BlinkLab's sensory assessments**.



Discuss other applications for the technology and other trials underway.

blinklab

European ADHD Study¹

- **Collaborator:** Mental Care Group
- **Goal:** Develop BlinkLab Dx 2 ADHD Model
- **Status:** Recruiting. Recently expanded from 1 to 5 ADHD clinical sites, 300 children will have completed all testing in mid-Q4



European Dementia Study²

- **Collaborator:** Erasmus University Medical Center
- **Goal:** Early neurometric markers for frontotemporal and Alzheimer's dementia
- **Status:** Recruiting presymptomatic and symptomatic participants



Australian MAGNET Study³

- **Collaborator:** Monash University
- **Goal:** Genotyping and deep behavioral phenotyping of autism and ADHD
- **Status:** Recruiting in the 1,000-family study

More info: <https://www.monash.edu/turner-institute/research/project-magnet>



blinklab *ASX:BB1*



Henk-Jan Boele (MD, PhD)
Co-founder and CEO

henkjan@blinklab.org

M: +31 (0) 611 132 247



Brian Leedman
Non-Executive Chairman
brian@blinklab.org

M: +61 (0) 412 281 780



info@blinklab.org



[@BlinkLab.App](https://www.instagram.com/BlinkLab.App)



[@Blink_Lab](https://twitter.com/Blink_Lab)



[BlinkLab Limited \(ASX:BB1\)](https://www.linkedin.com/company/BlinkLab%20Limited)



[@BlinkLab Ltd](https://www.facebook.com/BlinkLab.Ltd)



[@BlinkLab2193](https://www.youtube.com/channel/UCBkL2193)